Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas

Cancer

Volumn 88, Issue 6, 2000, Pages 1410-1416

  Utada, Yoshihito ^a,b   Haga, Shunsuke ^b   Kajiwara, Tetsuro ^b   Kasumi, Fujio ^c   Sakamoto, Goi ^c   Nakamura, Yusuke ^d   Emi, Mitsuru ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c CANCER INSTITUTE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Breast carcinoma; Chromosome 8; Loss of heterozygosity; Postoperative survival; Prognostic factor

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CHROMOSOME 8P; CONTROLLED STUDY; FEMALE; FOLLOW UP; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 8; COHORT STUDIES; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034654505     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1410::AID-CNCR19>3.0.CO;2-X     Document Type: Article

References (27)

1. Callahan R, Campbell. Mutations in human breast cancer: an overview. J Natl Cancer Inst 1989;81:1780-6.
2. Knudson AG. Anti-oncogenes and human cancer. Proc Natl Acad Sci U S A 1993;90:10914-21.
3. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsusda H, Hirohashi S, et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992;52:5368-72.
4. Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1993;7:152-7.
5. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T, et al. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 1993;53:1172-4.
6. Suzuki K, Emi M, Koyama A, Fujiwara Y, Yatani R, Nakamura Y, et al. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995;13: 168-74.
7. Knowles MA, Shaw ME, Proctor AJ. Deletion mapping of chromosome polymorphisms and microsatellite polymorphisms. Oncogene 1993;8:1357-64.
8. Ohata H, Emi M, Fujiwara Y, Higashino K, Nakagawa K, Futagami R, et al. Deletion mapping of the short arms of chromosome 8 in non-small cell lung carcinoma. Genes Chromosomes Cancer 1993;7:85-8.
9. Fabienne K, Laurent E, Amel D, Noguti T, Florrence A, Jeanine G, et al. A putive third susceptibility gene on the short arm of chromosome 8. Oncogene 1995;10:1023-6.
10. Yaremko ML, Recant WM, Westbrook CA. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 1995;13:186-91.
11. Seitz S, Rohde K, Bender E, Noyhnagel A, Pidde H, Ullrich OM, et al. Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis. Br J Cancer 1997;76:983-91.
12. Yokota T, Yoshimoto M, Kasumi F, Sakamoto G, Nakamura Y, Emi M. Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23.1. Cancer 1999;85:447-52.
13. Harris JR, Henderson IC. Staging and prognostic factors. In: Harris JR, editor. Breast diseases. Philadelphia: Lippincott, 1987:327-46.
14. McGuire W, Clark G. Prognostic factors and treatment decision in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-61.
15. Japanese Breast Cancer Society. The general rules for clinical and pathological recording of breast cancer. Jpn J Surg 1989;19:612-32.
16. Iida A, Yoshimoto M, Kasumi F, Nakamura Y, Emi M. Localization of breast cancer tumor-suppressor gene to a 3-cM interval within chromosomal region 16q22. Br J Cancer 1997; 75264-7.
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WM. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177-82.
18. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. Alterations to either c-erbB2 or c-myc proto-oncogenes in breast carcinoma correlate with poor short-term prognosis. Oncogene 1987;1:423-30.
19. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fearon M, Fuqua SAW, et al. HER-2/ neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50: 4332-7.
20. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Igurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991;6:137-143.
21. Berns EM, klijn JGM, Van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER-2/neu, and int-2 in one thousand human breast tumors: correlation with steroid receptors. Eur J Cancer 1992;213:697-700.
22. Tompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, et al. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 1990;61: 74-8.
23. Elledge RM, Fuqua SAW, Clark GM, Allred DC, McGuire WL. Prognostic significance of p53 gene mutations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-35.
24. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, et al. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 1994;54:499-505.
25. Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1992;339:139-43.
26. Catzavelos C, Bhattacharya N, Ung Y, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27-Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
27. Porter P, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27-kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.